Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Keith Denkler

Plastic Surgery Larkspur, CA Medical Doctor

NPI 1881783041 CMS profile 758768

275 Magnolia Ave, Larkspur, CA 94939

Open in the dashboard

General payments

$32,396

173 records reported · program years 2019–2025

Research payments

$2,925

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Keith Denkler of Larkspur, CA is reported in the CMS Open Payments database as having received $32,396 across 173 general payments and $2,925 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $751 12
2024 General $1,750 28
2023 General $429 15
2022 General $5,916 26
2021 General $427 20
2021 Research $2,925 5
2020 General $19,020 36
2019 General $4,103 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith Denkler
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Keith Denkler were reported at $751. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Keith Denkler Plastic Surgery median Middle half National median
2019 $4,103 $371 $122–$1,483 $163
2020 $19,020 $158 $52–$438 $114
2021 $427 $249 $87–$752 $132
2022 $5,916 $274 $102–$793 $149
2023 $429 $299 $113–$891 $160
2024 $1,750 $361 $124–$1,062 $164
2025 $751 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AcelRx Pharmaceuticals, Inc. $22,655 54 payments
  2. Endo Pharmaceuticals Inc. $6,168 37 payments
  3. AbbVie, Inc. $1,893 24 payments
  4. Allergan Inc. $705 33 payments
  5. Endo USA, Inc. $311 10 payments
  6. Mentor Worldwide LLC $294 3 payments
  7. Revance Therapeutics, Inc. $191 6 payments
  8. AxoGen $74 1 payment
  9. Smith+Nephew, Inc. $27 1 payment
  10. Apyx Medical Corporation $23 1 payment
  11. Other $56 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $15,700 8 payments
  2. Consulting Fee $8,240 3 payments
  3. Food and Beverage $4,288 130 payments
  4. Travel and Lodging $2,861 15 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,268 11 payments
  6. Education $38 6 payments
Products named General payments · program years 2019–2025
  1. DSUVIA $22,630 53 payments
  2. XIAFLEX $6,479 47 payments
  3. BOTOX $537 18 payments
  4. BOTOX COSMETIC $267 8 payments
  5. DAXXIFY $191 6 payments
  6. MENTOR MemoryGel Resterilizable Gel Sizer $148 2 payments
  7. MENTOR CPX 2 Breast Tissue Expander $146 1 payment
  8. AXOGUARD NERVE PROTECTOR $74 1 payment
  9. AxoGuard Nerve Connector $74 1 payment
  10. GRAFIX $27 1 payment
  11. Other $129 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Endo Pharmaceuticals Inc. $2,925 5 payments

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$181,814

Of which drugs: $133,670

Medicare patients

166

Average age 75

Services billed

2,890

73 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 51%
Arthritis 43%
Ischemic heart disease 18%
Osteoporosis 16%
Atrial fibrillation 14%
Cancer 14%
Chronic kidney disease 13%
Depression 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, collagenase, clostridium histolyticum, 0.01 mg J0775 Office 17 2,430 $133,649
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 28 $21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIAFLEX
  • Endo USA, Inc. $237
  • Endo Pharmaceuticals Inc. $22
$259 — 2,430
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $161
$161 — —
BOTOX
  • AbbVie, Inc. $108
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record